Open access
Clostridium Butyricum and butyrate enhance PD-1 inhibitor therapy in non-small cell lung cancer by regulating the HDAC1/ID2/IL-12R pathway
Zhuo Chen
Meng-Lei Wang
Zhuo-Wen Zhang
Pengcheng Zhang
Qing-Fang Yang
Yujing Weng
Jialong Shen
Wen-Xian Wang
Lan Shao
Medicine
Abstract
Highlights • NaB and C. butyricum enhance PD-1 inhibitor activity in NSCLC.• NaB and C. butyricum offer an alternative therapeutic mechanism via HDAC1 inhibition.• NaB cooperates with the PD-1 inhibitors depending on CD8+ T cells in NSCLC.